181 related articles for article (PubMed ID: 33996274)
1. Function, structure and quality of striated muscles in the lower extremities in patients with late onset Pompe Disease-an MRI study.
Vaeggemose M; Mencagli RA; Hansen JS; Dräger B; Ringgaard S; Vissing J; Andersen H
PeerJ; 2021; 9():e10928. PubMed ID: 33996274
[TBL] [Abstract][Full Text] [Related]
2. Follow-up of late-onset Pompe disease patients with muscle magnetic resonance imaging reveals increase in fat replacement in skeletal muscles.
Nuñez-Peralta C; Alonso-Pérez J; Llauger J; Segovia S; Montesinos P; Belmonte I; Pedrosa I; Montiel E; Alonso-Jiménez A; Sánchez-González J; Martínez-Noguera A; Illa I; Díaz-Manera J
J Cachexia Sarcopenia Muscle; 2020 Aug; 11(4):1032-1046. PubMed ID: 32129012
[TBL] [Abstract][Full Text] [Related]
3. Muscle imaging data in late-onset Pompe disease reveal a correlation between the pre-existing degree of lipomatous muscle alterations and the efficacy of long-term enzyme replacement therapy.
Gruhn KM; Heyer CM; Güttsches AK; Rehmann R; Nicolas V; Schmidt-Wilcke T; Tegenthoff M; Vorgerd M; Kley RA
Mol Genet Metab Rep; 2015 Jun; 3():58-64. PubMed ID: 26937398
[TBL] [Abstract][Full Text] [Related]
4. Correlation Between Respiratory Accessory Muscles and Diaphragm Pillars MRI and Pulmonary Function Test in Late-Onset Pompe Disease Patients.
Reyes-Leiva D; Alonso-Pérez J; Mayos M; Nuñez-Peralta C; Llauger J; Belmonte I; Pedrosa-Hernández I; Segovia S; Díaz-Manera J
Front Neurol; 2021; 12():621257. PubMed ID: 33732206
[No Abstract] [Full Text] [Related]
5. Bioimpedance Phase Angle as a Prognostic Tool in Late-Onset Pompe Disease: A Single-Centre Prospective Study With a 15-year Follow-Up.
Ravaglia S; de Giuseppe R; Carlucci A; Jehne S; Crescimanno G; Ahmad L; Paoletti M; Clemente G; Pichiecchio A; Bazzano R; Cirio S; Valente EM; Danesino C; De Filippi P; Tartara A; Cena H
Front Cell Dev Biol; 2022; 10():793566. PubMed ID: 35252175
[No Abstract] [Full Text] [Related]
6. Magnetization Transfer Ratio in Lower Limbs of Late Onset Pompe Patients Correlates With Intramuscular Fat Fraction and Muscle Function Tests.
Nuñez-Peralta C; Montesinos P; Alonso-Jiménez A; Alonso-Pérez J; Reyes-Leiva D; Sánchez-González J; Llauger-Roselló J; Segovia S; Belmonte I; Pedrosa I; Martínez-Noguera A; Matellini-Mosca B; Walter G; Díaz-Manera J
Front Neurol; 2021; 12():634766. PubMed ID: 33796064
[No Abstract] [Full Text] [Related]
7. Effect of enzyme replacement therapy on isokinetic strength for all major muscle groups in four patients with Pompe disease-a long-term follow-up.
Andreassen CS; Schlütter JM; Vissing J; Andersen H
Mol Genet Metab; 2014 May; 112(1):40-3. PubMed ID: 24685124
[TBL] [Abstract][Full Text] [Related]
8. Quantification of intramuscular fat in patients with late-onset Pompe disease by conventional magnetic resonance imaging for the long-term follow-up of enzyme replacement therapy.
Lollert A; Stihl C; Hötker AM; Mengel E; König J; Laudemann K; Gökce S; Düber C; Staatz G
PLoS One; 2018; 13(1):e0190784. PubMed ID: 29315315
[TBL] [Abstract][Full Text] [Related]
9. Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD).
Ripolone M; Violano R; Ronchi D; Mondello S; Nascimbeni A; Colombo I; Fagiolari G; Bordoni A; Fortunato F; Lucchini V; Saredi S; Filosto M; Musumeci O; Tonin P; Mongini T; Previtali S; Morandi L; Angelini C; Mora M; Sandri M; Sciacco M; Toscano A; Comi GP; Moggio M
Neuropathol Appl Neurobiol; 2018 Aug; 44(5):449-462. PubMed ID: 28574618
[TBL] [Abstract][Full Text] [Related]
10. Regional variation of thigh muscle fat infiltration in patients with neuromuscular diseases compared to healthy controls.
Greve T; Burian E; Zoffl A; Feuerriegel G; Schlaeger S; Dieckmeyer M; Sollmann N; Klupp E; Weidlich D; Inhuber S; Löffler M; Montagnese F; Deschauer M; Schoser B; Bublitz S; Zimmer C; Karampinos DC; Kirschke JS; Baum T
Quant Imaging Med Surg; 2021 Jun; 11(6):2610-2621. PubMed ID: 34079727
[TBL] [Abstract][Full Text] [Related]
11. Whole-body magnetic resonance imaging in late-onset Pompe disease: Clinical utility and correlation with functional measures.
Khan AA; Boggs T; Bowling M; Austin S; Stefanescu M; Case L; Kishnani PS
J Inherit Metab Dis; 2020 May; 43(3):549-557. PubMed ID: 31710733
[TBL] [Abstract][Full Text] [Related]
12. Isokinetic strength and degeneration of lower extremity muscles in patients with myotonic dystrophy; an MRI study.
Steenkjaer CH; Mencagli RA; Vaeggemose M; Andersen H
Neuromuscul Disord; 2021 Mar; 31(3):198-211. PubMed ID: 33568272
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy of the enzyme replacement therapy in patients with late-onset Pompe disease: a systematic review and a meta-analysis.
Sarah B; Giovanna B; Emanuela K; Nadi N; Josè V; Alberto P
J Neurol; 2022 Feb; 269(2):733-741. PubMed ID: 33851281
[TBL] [Abstract][Full Text] [Related]
14. Quantitative whole-body magnetic resonance imaging in children with Pompe disease: Clinical tools to evaluate severity of muscle disease.
Fernandes SA; Khan AA; Boggs T; Bowling M; Austin S; Stefanescu M; Case L; Kishnani PS
JIMD Rep; 2021 Jan; 57(1):94-101. PubMed ID: 33473345
[TBL] [Abstract][Full Text] [Related]
15. Positive association between physical outcomes and patient-reported outcomes in late-onset Pompe disease: a cross sectional study.
Yuan M; Andrinopoulou ER; Kruijshaar ME; Lika A; Harlaar L; van der Ploeg AT; Rizopoulos D; van der Beek NAME
Orphanet J Rare Dis; 2020 Sep; 15(1):232. PubMed ID: 32883321
[TBL] [Abstract][Full Text] [Related]
16. Distribution of Exonic Variants in Glycogen Synthesis and Catabolism Genes in Late Onset Pompe Disease (LOPD).
De Filippi P; Errichiello E; Toscano A; Mongini T; Moggio M; Ravaglia S; Filosto M; Servidei S; Musumeci O; Giannini F; Piperno A; Siciliano G; Ricci G; Di Muzio A; Rigoldi M; Tonin P; Croce MG; Pegoraro E; Politano L; Maggi L; Telese R; Lerario A; Sancricca C; Vercelli L; Semplicini C; Pasanisi B; Bembi B; Dardis A; Palmieri I; Cereda C; Valente EM; Danesino C
Curr Issues Mol Biol; 2023 Apr; 45(4):2847-2860. PubMed ID: 37185710
[TBL] [Abstract][Full Text] [Related]
17. A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe disease.
Byrne BJ; Geberhiwot T; Barshop BA; Barohn R; Hughes D; Bratkovic D; Desnuelle C; Laforet P; Mengel E; Roberts M; Haroldsen P; Reilley K; Jayaram K; Yang K; Walsh L;
Orphanet J Rare Dis; 2017 Aug; 12(1):144. PubMed ID: 28838325
[TBL] [Abstract][Full Text] [Related]
18. Quantitative muscle MRI to follow up late onset Pompe patients: a prospective study.
Figueroa-Bonaparte S; Llauger J; Segovia S; Belmonte I; Pedrosa I; Montiel E; Montesinos P; Sánchez-González J; Alonso-Jiménez A; Gallardo E; Illa I; ; Díaz-Manera J
Sci Rep; 2018 Jul; 8(1):10898. PubMed ID: 30022036
[TBL] [Abstract][Full Text] [Related]
19. Six-Minute Walk Distance Is a Useful Outcome Measure to Detect Motor Decline in Treated Late-Onset Pompe Disease Patients.
Claeys KG; D'Hondt A; Fache L; Peers K; Depuydt CE
Cells; 2022 Jan; 11(3):. PubMed ID: 35159144
[TBL] [Abstract][Full Text] [Related]
20. Residual Deficits of Knee Flexors and Plantar Flexors Predict Normalized Walking Performance in Patients with Poststroke Hemiplegia.
Ozgozen S; Guzel R; Basaran S; Coskun Benlidayi I
J Stroke Cerebrovasc Dis; 2020 Apr; 29(4):104658. PubMed ID: 32037268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
